The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
Sara Markowitz () and
American Economic Journal: Economic Policy, 2010, vol. 2, issue 4, 1-25
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of inappropriate drug prescriptions, leading to regulatory actions against the firm. We empirically test the relationship between drug promotion and reporting of ADRs using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and ADRs. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of ADRs for certain conditions. (JEL L51, L65, M31, M37)
JEL-codes: L51 L65 M31 M37 (search for similar items in EconPapers)
Note: DOI: 10.1257/pol.2.4.1
References: View references in EconPapers View complete reference list from CitEc
Citations View citations in EconPapers (5) Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to AEA members and institutional subscribers.
Working Paper: The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation (2009)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:aea:aejpol:v:2:y:2010:i:4:p:1-25
Ordering information: This journal article can be ordered from
Access Statistics for this article
American Economic Journal: Economic Policy is currently edited by Alan J. Auerbach
More articles in American Economic Journal: Economic Policy from American Economic Association Contact information at EDIRC.
Series data maintained by Jane Voros ().